<DOC>
	<DOCNO>NCT00844441</DOCNO>
	<brief_summary>RATIONALE : Gathering information patient myelodysplastic syndrome acute myeloid leukemia discharge finish chemotherapy , stay hospital blood count return normal , may help doctor learn patient 's quality life , use medical service , cost service . PURPOSE : This clinical trial study early discharge outpatient care patient undergone chemotherapy myelodysplastic syndrome acute myeloid leukemia .</brief_summary>
	<brief_title>Early Discharge Outpatient Care After Chemotherapy Patients With Myelodysplastic Syndrome Acute Myeloid Leukemia</brief_title>
	<detailed_description>OBJECTIVES : Primary - To compare death rate patient myelodysplastic syndrome acute myeloid leukemia discharge completion induction chemotherapy v remain hospital blood count recover . Secondary - To determine proportion patient meet early discharge criterion completion induction chemotherapy . - To compare cost incurred patient discharge early v discharge blood count recover . - To compare resource utilization ( e.g. , transfusion ) among patient . - To compare quality life patient . OUTLINE : Within 72 hour completion induction chemotherapy , patient either discharged hospital remain hospital blood count recover . Patients receive standard supportive care completion induction chemotherapy either hospital outpatient . Outpatients see registered nurse physician assistant ≥ 3 time weekly physician least weekly . A medical chart review conduct obtain information medical complication ( e.g. , neutropenic fever , documented infection , bleeding , reason hospitalization ) use medical resource . Patients complete MDA Symptom Inventory EORTC QLQ-C30 questionnaire periodically assess quality life . Costs associate inpatient outpatient care evaluate use electronic billing information University Washington Medical Center Seattle Cancer Care Alliance . After completion study , patient follow 1 month .</detailed_description>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Diagnosis one following : Myelodysplastic syndrome Acute myeloid leukemia ( AML ) No acute promyelocytic leukemia ( 15 ; 17 ) ( q22 ; q12 ) , PML/RAR , variant Planning undergo AMLlike intensive induction chemotherapy ( e.g. , `` 7+3 '' regimen similar high intensity ) untreated relapsed disease within 1 week study entry OR start therapy within past 72 hour PATIENT CHARACTERISTICS : No hypersensitivity allergy fluoroquinolones , triazoles , acyclovir ECOG/WHO/ZUBROD performance status 01* Total bilirubin ≤ 2.5 time upper limit normal ( ULN ) ( unless elevation thought due Gilbert 's syndrome hemolysis ) * AST ALT ≤ 1.5 time ULN* Serum creatinine ≤ 1.5 time ULN* No clinical evidence congestive heart failure* No active bleeding* Not refractory platelet transfusion ( e.g. , due HLAalloimmunization ) * No requirement IV antimicrobial therapy* Agrees undergo close followup include ≥ 3 visit per week Seattle Cancer Care Alliance ( SCCA ) * Has confirm reliable caregiver transportation* Confirmed temporary permanent residency within 30minute commute University Washington ( UW ) Medical Center/SCCA* Has identify UW/SCCA hematologist/oncologist willing care patient outpatient clinic* NOTE : *Additional criterion early discharge hospital PRIOR CONCURRENT THERAPY : See Disease Characteristics</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>60 Years</maximum_age>
	<verification_date>May 2011</verification_date>
	<keyword>de novo myelodysplastic syndrome</keyword>
	<keyword>previously treat myelodysplastic syndrome</keyword>
	<keyword>secondary myelodysplastic syndrome</keyword>
	<keyword>recurrent adult acute myeloid leukemia</keyword>
	<keyword>untreated adult acute myeloid leukemia</keyword>
	<keyword>adult acute myeloid leukemia inv ( 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 16 ; 16 ) ( p13 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia ( 8 ; 21 ) ( q22 ; q22 )</keyword>
	<keyword>adult acute myeloid leukemia 11q23 ( MLL ) abnormality</keyword>
	<keyword>adult acute minimally differentiate myeloid leukemia ( M0 )</keyword>
	<keyword>adult acute myeloblastic leukemia without maturation ( M1 )</keyword>
	<keyword>adult acute myeloblastic leukemia maturation ( M2 )</keyword>
	<keyword>adult acute myelomonocytic leukemia ( M4 )</keyword>
	<keyword>adult acute monoblastic leukemia ( M5a )</keyword>
	<keyword>adult acute eosinophilic leukemia</keyword>
	<keyword>adult acute monocytic leukemia ( M5b )</keyword>
	<keyword>adult acute megakaryoblastic leukemia ( M7 )</keyword>
	<keyword>adult acute basophilic leukemia</keyword>
	<keyword>acute myeloid leukemia multilineage dysplasia follow myelodysplastic syndrome</keyword>
	<keyword>adult erythroleukemia ( M6a )</keyword>
	<keyword>adult pure erythroid leukemia ( M6b )</keyword>
</DOC>